Equine sarcoids are the most common skin tumors in horses, causing welfare harm from irritation, progressive growth, and the often difficult and painful treatment process.
Sarcoid welfare management requires balancing the welfare cost of progressive lesion growth against the often significant welfare cost of treatment. Some treatment modalities — particularly topical chemotherapy — cause acute inflammation, pain, and tissue necrosis at the treatment site before eventual resolution. The decision to treat must weigh lesion location, growth rate, functional impact, and treatment welfare cost against the likely outcome. Periorbital lesions that threaten vision, perigenital lesions causing discomfort during urination, and rapidly growing lesions causing persistent irritation have clear treatment indications. Stable flat lesions in non-problematic locations may warrant watchful waiting. Treatment planning should involve an equine dermatologist or oncologist to select the approach most likely to achieve complete resolution while minimizing treatment welfare costs.